Close

Arena Pharma (ARNA) to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. TSLA
3. SPY
4. ADBE
5. CPRI
6. NVDA
7. VERX
8. RIL:IN
9. TPR
10. CLF


Go back to Arena Pharma (ARNA) to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference

Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference

December 11, 2020 9:00 AM EST

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the... More